EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Intranasal Delivery of Metabolically Resilient Glutathione: In Vivo Pharmacokinetic, Permeation, and Efficacy Studies

Kiran D Bhilare, Prakashkumar Dobariya, Antonio Lee, Wei Xie, Jiashu Xie iD, Joyce Meints, Robert Vince, Michael K Lee, Swati S More iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c00382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Kiran D Bhilare und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, United States. Hauptthemen laut MEDLINE: Glutathione, Alzheimer Disease, Neuroprotective Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, Center for Drug Design, University of Minnesota, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nose-to-brain delivery is an attractive drug delivery strategy for the treatment of Alzheimer's disease (AD) as it offers direct penetration of drugs into the brain by surpassing the blood-brain barrier, while reducing the potential systemic side effects. We developed a glutathione analogue, ψ-GSH, that resists catabolism and reduces AD-related behavioral and pathological abnormalities in vivo. Although ψ-GSH is effective via intraperitoneal administration, limited oral availability hinders the clinical translation of ψ-GSH. In this study, we sought to evaluate if intranasal ψ-GSH administration can provide neuroprotection in an acute mouse model of AD-related pathology. The pharmacokinetic analysis confirmed brain delivery of the compound to levels 4-fold higher than those achieved by an efficacious systemic dose of ψ-GSH. Unaffected stability in simulated nasal fluid and mucosa further displayed the feasibility of this delivery method. Repeated intranasal administration of ψ-GSH prevented cognitive impairment induced by the intracerebroventricular injection of Aβ1-42 without significant adverse effects. Biochemical and immunohistochemical analyses displayed the beneficial effect of the treatment on oxidative stress and inflammatory markers by engaging GSH-dependent mechanisms, mirroring the pharmacological effects of intraperitoneal ψ-GSH. Additionally, in vitro directional transport studies using a human nasal epithelial cell line showed directional brain transport of ψ-GSH, without compromising the integrity of tight junction proteins. Collectively, our results demonstrate intranasal delivery as a safe and effective alternative for brain delivery of ψ-GSH at pharmacologically relevant concentrations for the treatment of neurological conditions. The study supports future formulation studies for intranasal ψ-GSH administration and its efficacy evaluation in transgenic AD mouse models for preclinical advancement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlutathioneAlzheimer DiseaseNeuroprotective AgentsAnimalsAdministration, IntranasalMiceBrainDisease Models, AnimalOxidative StressMaleBlood-Brain BarrierAmyloid beta-PeptidesHumansNasal MucosaMice, Inbred C57BLDrug Delivery Systems

Stichwörter der Autor:innen

intranasalneurodegenerationoxidative stresspermeationstabilityψ-GSH

Substanzen

GlutathioneAmyloid beta-PeptidesNeuroprotective Agents

Autor:innen und Institutionen

  • Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, United States.
  • Department of Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States.
  • Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States.

ORCID-Profile: Jiashu Xie, Swati S More

Förderung

  • NIA NIH HHS
  • Center for Drug Design, University of Minnesota
  • National Institute on Aging

Zitieren

APA

Bhilare, K. D., Dobariya, P., Lee, A., Xie, W., Xie, J., Meints, J., Vince, R., Lee, M. K., & More, S. S. (2025). Intranasal Delivery of Metabolically Resilient Glutathione: In Vivo Pharmacokinetic, Permeation, and Efficacy Studies. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00382

Vancouver

Bhilare KD, Dobariya P, Lee A, Xie W, Xie J, Meints J, et al. Intranasal Delivery of Metabolically Resilient Glutathione: In Vivo Pharmacokinetic, Permeation, and Efficacy Studies. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00382

BibTeX
@article{Bhilare2025,
  author = {Bhilare, Kiran D and Dobariya, Prakashkumar and Lee, Antonio and Xie, Wei and Xie, Jiashu and Meints, Joyce and Vince, Robert and Lee, Michael K and More, Swati S},
  title = {Intranasal Delivery of Metabolically Resilient Glutathione: In Vivo Pharmacokinetic, Permeation, and Efficacy Studies},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c00382}
}
Kostenlos starten →